Synergistic vasculogenic effects of AMD3100 and stromal-cell-derived factor-1α in vasa nervorum of the sciatic nerve of mice with diabetic peripheral neuropathy.
Autologous endothelial progenitor cell (EPC) transplantation has been suggested as a potential therapeutic approach in diabetic neuropathy (DN). However, such treatment might be limited by safety concerns regarding possible unwanted proliferation or differentiation of the transplanted stem cells. An alternative approach is the stimulation of endogenous bone-marrow-derived EPC (BM-EPC) recruitment into ischemic lesions by the administration of stem cell mobilization agents or chemokines. We first tested the EPC mobilization effect of vascular endothelial growth factor (VEGF) and AMD3100 in a mouse model of diabetes and found that AMD3100 was effective as an EPC mobilization agent, whereas VEGF did not increase circulating EPCs in these animals. Because recent studies have suggested that deceased local expression of stromal-cell-derived factor (SDF)-1α in diabetes is the main cause of defective EPC migration, AMD3100 was administrated systemically to stimulate EPC mobilization and SDF-1α was injected locally to enhance its migration into the streptozotocin-induced DN mice model. This combined therapy increased local expression levels of vasculogenesis-associated factors and newly formed endothelial cells in the sciatic nerve, resulting in the restoration of the sciatic vasa nervorum. The treatment also improved the impaired conduction velocity of the sciatic nerve in DN mice. Thus, AMD3100 might be an effective EPC mobilization agent in diabetes, with local SDF-1α injection synergistically increasing vascularity in diabetic nerves. This represents a novel potential therapeutic option for DN patients.
Stem Cell Neuroplasticity Research Group, Kyungpook National University, Daegu, South Korea.
Bae Jin
BJ
Kim
Jong Kil
JK
Lee
Edward H
EH
Schuchman
Hee Kyung
HK
Jin
Jae-sung
JS
Bae
D000818:Animals; D001596:Benzylamines; D054377:Chemokine CXCL12 / Q000008:administration & dosage / Q000627:therapeutic use*; D000080027:Cyclams; D003929:Diabetic Neuropathies / Q000188:drug therapy* / Q000473:pathology; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000473:pathology; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D012584:Sciatic Nerve / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects; D014650:Vasa Nervorum / Q000187:drug effects*
D001596:Benzylamines; D054377:Chemokine CXCL12; D000080027:Cyclams; D006571:Heterocyclic Compounds; D019718:Receptors, CXCR4; C088327:plerixafor